Abstract
The development of new antimicrobial agents for the treatment of infectious diseases remains challenging due to the increasing impact of antibiotic resistance. Since salicylanilides and esters of pyrazine-2-carboxylic acid have been described as potential antimicrobials, we have designed and synthesized a series of 2-(phenylcarbamoyl)phenyl pyrazine-2-carboxylates. These were evaluated in vitro for the activity against fungi and Gram-positive and Gram-negative bacteria. All derivatives showed significant antibacterial activity against Gram-positive strains (MIC ≥ 0.98 µmol/L) including methicillin-resistant Staphylococcus aureus. The most active molecule was 5-chloro-2-(3-chlorophenylcarbamoyl)phenyl pyrazine-2-carboxylate. With one exception these esters were at least partly active against fungi tested strains, in particular against mould strains (MIC ≥ 1.95 µmol/L). The most active antifungal agent overall proved to be 2-(4-bromophenylcarbamoyl)-4-chlorophenyl pyrazine-2-carboxylate.
Keywords: Antibacterial activity, antifungal activity, in vitro activity, pyrazine-2-carboxylic acid ester, salicylanilide, salicylanilide ester, salicylanilide, Clostridium difficile, Staphylococcus aureus, MRSA, fungal pathogens
Medicinal Chemistry
Title:In Vitro Antibacterial and Antifungal Activity of Salicylanilide Pyrazine-2- carboxylates
Volume: 8 Issue: 4
Author(s): Martin Kratky, Jarmila Vinsova and Vladimir Buchta
Affiliation:
Keywords: Antibacterial activity, antifungal activity, in vitro activity, pyrazine-2-carboxylic acid ester, salicylanilide, salicylanilide ester, salicylanilide, Clostridium difficile, Staphylococcus aureus, MRSA, fungal pathogens
Abstract: The development of new antimicrobial agents for the treatment of infectious diseases remains challenging due to the increasing impact of antibiotic resistance. Since salicylanilides and esters of pyrazine-2-carboxylic acid have been described as potential antimicrobials, we have designed and synthesized a series of 2-(phenylcarbamoyl)phenyl pyrazine-2-carboxylates. These were evaluated in vitro for the activity against fungi and Gram-positive and Gram-negative bacteria. All derivatives showed significant antibacterial activity against Gram-positive strains (MIC ≥ 0.98 µmol/L) including methicillin-resistant Staphylococcus aureus. The most active molecule was 5-chloro-2-(3-chlorophenylcarbamoyl)phenyl pyrazine-2-carboxylate. With one exception these esters were at least partly active against fungi tested strains, in particular against mould strains (MIC ≥ 1.95 µmol/L). The most active antifungal agent overall proved to be 2-(4-bromophenylcarbamoyl)-4-chlorophenyl pyrazine-2-carboxylate.
Export Options
About this article
Cite this article as:
Kratky Martin, Vinsova Jarmila and Buchta Vladimir, In Vitro Antibacterial and Antifungal Activity of Salicylanilide Pyrazine-2- carboxylates, Medicinal Chemistry 2012; 8 (4) . https://dx.doi.org/10.2174/157340612801216346
DOI https://dx.doi.org/10.2174/157340612801216346 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Co-agonist Site of NMDA-glutamate Receptors: A Novel Therapeutic Target for Age-related Cognitive Decline
Current Pharmaceutical Design Inhaled Formulation Design for the Treatment of Lung Infections
Current Pharmaceutical Design Antimicrobial Potential of Botanicals and Disease Control
The Natural Products Journal Liposome-Nanogel Structures for Future Pharmaceutical Applications
Current Pharmaceutical Design Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Targeting Tumor Necrosis Factor-α in the Therapy of Psoriasis
Current Drug Targets - Inflammation & Allergy Effects of Chrisotherapeutic Gold Compounds on Prostaglandin E2 Production
Current Drug Targets - Inflammation & Allergy Inhaled Dry Powder Formulations for Treating Tuberculosis
Current Drug Delivery Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide
Current Organic Synthesis Discovery of Potential Dual Inhibitors Against Lipases Rv0183 and Rv3802c for Tuberculosis Therapeutics
Letters in Drug Design & Discovery DC-SIGN Antagonists, a Potential New Class of Anti-Infectives
Current Medicinal Chemistry Transcriptional Responses of Mycobacterium tuberculosis Exposed to Adverse Conditions In Vitro
Current Molecular Medicine Nitric Oxide: Friendly Rivalry in Tuberculosis
Current Signal Transduction Therapy Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Developing Solid Particulate Vaccine Adjuvants: Surface Bound Antigen Favours a Humoural Response, whereas Entrapped Antigen Shows a Tendency for Cell Mediated Immunity
Current Drug Delivery Meet the Editorial Board:
Current Medicinal Chemistry Patent Selections
Recent Patents on Nanomedicine Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry In Search of New Cures for Tuberculosis
Medicinal Chemistry